Analyst Mike McGlone warns that Bitcoin could fall to around $10,000 if the S&P 500 experiences a 20% drop that lasts for some time. He notes that Bitcoin's performance has closely tracked the S&P 500 over the past five years, though with higher volatility. McGlone suggests that if Bitcoin remains strong independently of equities, this downside scenario could be challenged. His view adds to previous forecasts of Bitcoin's potential decline amid weakening risk assets.
Regarding McGlone's Bitcoin outlook, here is Pluang's market snapshot as of Oct 17, 2026 12:02 WIB: Among 50 major cryptocurrencies priced on Pluang, 12 rose and 37 fell today. Notable movers include FIL (Filecoin) at Rp21.394 with a 1-day change of +3.27%, ATOM (Cosmos) at Rp31.746 with +2.79%, and SUSHI (SushiSwap) at Rp4.036 with -2.60%.
Shares of MARA, a major Bitcoin mining company, fell sharply by 10.12% intraday to $7.48. This decline reflects a significant loss in the company's stock value during the trading session, distinct from the price of Bitcoin itself. The drop indicates ...
Deutsche Bank is set to begin offering custody services for bitcoin, ether, and three e-money tokens to institutional clients within weeks, starting in Germany. This service, pending regulatory approval, targets asset managers, corporations, and stat...
Bitcoin briefly fell below $80,000 before recovering above $82,000 amid inflation data and ETF flows. Ledger tightened reseller rules after discovering hardware implants used to steal recovery phrases, enhancing device security. MSCI introduced new e...
Evernorth Holdings announced partnerships with Ripple, Kraken, Coinbase, and BitGo to manage institutional strategies involving its 473 million XRP treasury. These collaborations are planned to begin deploying in the fourth quarter of 2026, pending c...
AbbVie unveiled 20 new scientific presentations at the 2026 United European Gastroenterology Week, highlighting long-term and real-world data for its inflammatory bowel disease (IBD) treatments SKYRIZI (risankizumab) and RINVOQ (upadacitinib). The da...
